A novel role for SIRT-1 in L-Arginine protection against STZ induced myocardial fibrosis in rats

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Rizk, Sherine M ^a   El Maraghy, Shohda A ^a   Nassar, Noha N ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CASPASE 3; COLLAGEN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DRINKING WATER; FAS LIGAND; FIBRONECTIN; GELATINASE A; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SILENT INFORMATION REGULATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VESICULAR GLUTAMATE TRANSPORTER 1; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 1BETA; NAPHTHOL DERIVATIVE; SIRT1 PROTEIN, RAT; SIRTINOL; SIRTUIN 1; STREPTOZOCIN; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN INDUCED MYOCARDIAL FIBROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CARDIAC MUSCLE; CELL PROTECTION; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; APOPTOSIS; ARGININE; BENZAMIDES; BIOMARKERS; BLOOD GLUCOSE; CYTOPROTECTION; DIABETES COMPLICATIONS; FASTING; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; NAPHTHOLS; RATS; RATS, WISTAR; SIRTUIN 1; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918587309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114560     Document Type: Article

References (68)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
2. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, et al. (2009) Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58: 1373-1381.
3. Yu W, Wu J, Cai F, Xiang J, Zha W, et al. (2012) Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 7: e52013.
4. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, et al. (2010) Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 59: 1512-1520.
5. Falcao-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 17: 325-344.
6. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, et al. (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56: 641-646.
7. Chen S, Khan ZA, Cukiernik M, Chakrabarti S (2003) Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 284: E1089-1097.
8. Al-Maghrebi M, Benter IF, Diz DI (2009) Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268.
9. Gray S, Kim JK (2011) New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 22: 394-403.
10. Palomer X, Salvado L, Barroso E, Vazquez-Carrera M (2013) An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol 168: 3160-3172.
11. Lijnen P, Petrov V (2002) Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol 24: 333-344.
12. Petrov VV, Fagard RH, Lijnen PJ (2002) Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39: 258-263.
13. Vaughan MB, Howard EW, Tomasek JJ (2000) Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 257: 180-189.
14. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, et al. (2004) Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44: 1859-1866.
15. Pulla VK, Battu MB, Alvala M, Sriram D, Yogeeswari P (2012) Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review. Expert Opin Ther Targets 16: 819-832.
16. Yang J, Wang N, Zhu Y, Feng P (2011) Roles of SIRT1 in high glucose-induced endothelial impairment: association with diabetic atherosclerosis. Arch Med Res 42: 354-360.
17. Xie J, Zhang X, Zhang L (2013) Negative regulation of inflammation by SIRT1. Pharmacol Res 67: 60-67.
18. Liu CT, Chen KM, Lee SH, Tsai LJ (2005) Effect of supplemental L-arginine on the function of T lymphocytes and the formation of advanced glycosylated end products in rats with streptozotocin-induced diabetes. Nutrition 21: 615-623.
19. Tan B, Li X, Yin Y, Wu Z, Liu C, et al. (2012) Regulatory roles for L-arginine in reducing white adipose tissue. Front Biosci (Landmark Ed) 17: 2237-2246.
20. Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, et al. (2001) Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 163: 887-891.
21. Mohan IK, Das UN (1998) Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med 25: 757-765.
22. Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, et al. (2001) Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 24: 875-880.
23. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
24. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML (2008) Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 57: 2158-2166.
25. Yang Y, Duan W, Lin Y, Yi W, Liang Z, et al. (2013) SIRT1 activation by curcumin pretreatment attenuates mitochondrial oxidative damage induced by myocardial ischemia reperfusion injury. Free Radic Biol Med 65: 667-679.
26. Bisse E, Abraham EC (1985) New less temperature-sensitive microchromatographic method for the separation and quantitation of glycosylated hemoglobins using a non-cyanide buffer system. J Chromatogr 344: 81-91.
27. Luo L, Sun Z, Luo G (2013) Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy. J Surg Res 179: e255-263.
28. Woessner JF Jr (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93: 440-447.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
30. Szulinska M, Musialik K, Suliburska J, Lis I, Bogdanski P (2014) The effect of L-arginine supplementation on serum resistin concentration in insulin resistance in animal models. Eur Rev Med Pharmacol Sci 18: 575-580.
31. Mendez JD, Balderas FL (2006) Inhibition by L-arginine and spermidine of hemoglobin glycation and lipid peroxidation in rats with induced diabetes. Biomed Pharmacother 60: 26-31.
32. Hernandez-Jimenez M, Hurtado O, Cuartero MI, Ballesteros I, Moraga A, et al. (2013) Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke 44: 2333-2337.
33. Kain V, Kumar S, Puranik AS, Sitasawad SL (2010) Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol 9: 82.
34. Pai MH, Huang KH, Wu CH, Yeh SL (2010) Effects of dietary arginine on inflammatory mediator and receptor of advanced glycation endproducts (RAGE) expression in rats with streptozotocin-induced type 2 diabetes. Br J Nutr 104: 686-692.
35. Hwang JW, Yao H, Caito S, Sundar IK, Rahman I (2013) Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 61C: 95-110.
36. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, et al. (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34: 1610-1616.
37. Maruyama K, Asai J, Ii M, Thorne T, Losordo DW, et al. (2007) Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol 170: 1178-1191.
38. Wang W, Lin Q, Lin R, Zhang J, Ren F, et al. (2013) PPARalpha agonist fenofibrate attenuates TNF-alpha-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res 319: 1523-1533.
39. Kar M, Chakraborti AS (1999) Release of iron from haemoglobin-a possible source of free radicals in diabetes mellitus. Indian J Exp Biol 37: 190-192.
40. Khan ZA, Chakrabarti S (2007) Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007: 31867.
41. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN (2010) IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 58: 1082-1093.
42. Ortiz Mdel C, Lores-Arnaiz S, Albertoni Borghese MF, Balonga S, Lavagna A, et al. (2013) Mitochondrial dysfunction in brain cortex mitochondria of STZ-diabetic rats: effect of l-Arginine. Neurochem Res 38: 2570-2580.
43. Perez Gutierrez RM, de Jesus Martinez Ortiz M (2014) Beneficial effect of Azadirachta indica on advanced glycation end-product in streptozotocin-diabetic rat. Pharm Biol: 1-10.
44. Lin L (2006) RAGE on the Toll Road? Cell Mol Immunol 3: 351-358.
45. Sklavounou E, Hay A, Ashraf N, Lamb K, Brown E, et al. (2006) The use of telomere biology to identify and develop superior nitrone based anti-oxidants. Biochem Biophys Res Commun 347: 420-427.
46. Wang W, Yan C, Zhang J, Lin R, Lin Q, et al. (2013) SIRT1 inhibits TNF-alpha-induced apoptosis of vascular adventitial fibroblasts partly through the deacetylation of FoxO1. Apoptosis 18: 689-701.
47. Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, et al. (2001) Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 20: 1476-1485.
48. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, et al. (1997) Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 159: 1594-1598.
49. Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, et al. (2000) Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest 105: 1199-1208.
50. Hu WH, Johnson H, Shu HB (2000) Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem 275: 10838-10844.
51. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, et al. (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 8: 35.
52. Kohda Y, Shirakawa H, Yamane K, Otsuka K, Kono T, et al. (2008) Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 33: 459-472.
53. Leask A, Holmes A, Abraham DJ (2002) Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 4: 136-142.
54. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, et al. (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51: 2709-2718.
55. James LR, Le C, Doherty H, Kim HS, Maeda N (2013) Connective tissue growth factor (CTGF) expression modulates response to high glucose. PLOS One 8: e70441.
56. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, et al. (2009) TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 1792: 746-756.
57. Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106: 1675-1680.
58. Hermida N, Lopez B, Gonzalez A, Dotor J, Lasarte JJ, et al. (2009) A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81: 601-609.
59. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 195: 321-338.
60. Jesmin S, Hattori Y, Togashi H, Ueno K, Yoshioka M, et al. (2005) Age-related changes in cardiac expression of VEGF and its angiogenic receptor KDR in stroke-prone spontaneously hypertensive rats. Mol Cell Biochem 272: 63-73.
61. Miguel-Carrasco JL, Baltanas A, Cebrian C, Moreno MU, Lopez B, et al. (2012) Blockade of TGF-beta 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. Oxid Med Cell Longev 2012: 726940.
62. Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H (2007) Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). Int Heart J 48: 637-647.
63. Hutchinson KR, Lord CK, West TA, Stewart JA Jr (2013) Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes. PLOS One 8: e72080.
64. Zagotta I, Dimova EY, Funcke JB, Wabitsch M, Kietzmann T, et al. (2013) Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue. Oxid Med Cell Longev 2013: 793525.
65. Raffetto JD, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75: 346-359.
66. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, et al. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096.
67. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, et al. (2007) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292: H1847-1860.
68. Suboj P, Babykutty S, Valiyaparambil Gopi DR, Nair RS, Srinivas P, et al. (2012) Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. Eur J Pharm Sci 45: 581-591.